AGN — Algernon Pharmaceuticals Share Price
0.000.00%
Last trade - 00:00- CA$2.44m
- CA$2.08m
- 10
- 38
- 62
- 29
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.36 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -34.07% | ||
| Return on Equity | -25.89% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Aug | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CA$m | n/a | n/a | n/a | n/a | n/a | 1.5 | 1.5 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.
Directors
- Last Annual
- August 31st, 2024
- Last Interim
- November 30th, 2024
- Incorporated
- April 10th, 2015
- Public Since
- February 1st, 2016
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Canadian Securities Exchange
- Shares in Issue
- 28,706,219
- Address
- 400 - 601 WEST BROADWAY, VANCOUVER, V5Z 4C2
- Web
- https://algernonpharmaceuticals.com
- Phone
- +1 6043984175
- Auditors
- Smythe LLP
Upcoming Events for AGN
Similar to AGN
Albert Labs International
Canadian Securities Exchange
Asep Medical Holdings
Canadian Securities Exchange
Awakn Life Sciences
Canadian Securities Exchange
BetterLife Pharma
Canadian Securities Exchange
BioMark Diagnostics
Canadian Securities Exchange
FAQ
What is the Algernon Pharmaceuticals share price?
As of Today at 19:11 UTC, shares in Algernon Pharmaceuticals are trading at CA$0.09. This share price information is delayed by 15 minutes.
How has the Algernon Pharmaceuticals share price performed this year?
Shares in Algernon Pharmaceuticals last closed at CA$0.09 and the price had moved by -15% over the past 365 days. In terms of relative price strength the Algernon Pharmaceuticals share price has underperformed the Toronto Stock Exchange 300 Composite Index by -23.38% over the past year.
What are the analyst and broker recommendations for Algernon Pharmaceuticals?
The overall consensus recommendation for Algernon Pharmaceuticals is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Algernon Pharmaceuticals dividend yield?
Algernon Pharmaceuticals does not currently pay a dividend.
Does Algernon Pharmaceuticals pay a dividend?
Algernon Pharmaceuticals does not currently pay a dividend.
When does Algernon Pharmaceuticals next pay dividends?
Algernon Pharmaceuticals does not currently pay a dividend.
How do I buy Algernon Pharmaceuticals shares?
To buy shares in Algernon Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Algernon Pharmaceuticals?
As of the previous close price of CA$0.09, shares in Algernon Pharmaceuticals had a market capitalisation of CA$2.44m.
Where are Algernon Pharmaceuticals shares listed?
Here are the trading details for Algernon Pharmaceuticals:
- Country of listing: Canada
- Exchange: CNX
- Ticker Symbol: AGN
What kind of share is Algernon Pharmaceuticals?
Based on an overall assessment of its quality, value and momentum Algernon Pharmaceuticals is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Algernon Pharmaceuticals share price forecast for 2025?
The analyst consensus target price for shares in Algernon Pharmaceuticals is CA$2.56. That is 2911.76% above the last closing price of CA$0.09.
Analysts covering Algernon Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of -CA$0.54 for the next financial year.
Find out moreWhat is the trend in the Algernon Pharmaceuticals share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Algernon Pharmaceuticals. Over the past six months, its share price has outperformed the Toronto Stock Exchange 300 Composite Index by +2.19%.
As of the last closing price of CA$0.09, shares in Algernon Pharmaceuticals were trading -10.21% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Algernon Pharmaceuticals PE Ratio?
The Algernon Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at CA$0.09.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Algernon Pharmaceuticals?
We do not have data on Algernon Pharmaceuticals' directors